First-in-class angiotensin receptor neprilysin inhibitor in heart failure

O. Vardeny, T. Tacheny, S. D. Solomon

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide. LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction. A preserved ejection fraction outcomes trial is beginning.

Original languageEnglish (US)
Pages (from-to)445-448
Number of pages4
JournalClinical Pharmacology and Therapeutics
Issue number4
StatePublished - Oct 1 2013


Dive into the research topics of 'First-in-class angiotensin receptor neprilysin inhibitor in heart failure'. Together they form a unique fingerprint.

Cite this